Molecular Diagnostics · ₹768 – ₹807 · ₹939.7 Cr
Molbio Diagnostics Limited is an innovative point-of-care diagnostics company. It develops and commercializes healthcare technologies to diagnose infectious and non-communicable diseases, offering portable, battery-operated 'Truenat' platforms and disease-specific test kits. It also provides devices for radiology, digital pathology, and breast health screening. It operates in the Molecular Diagnostics industry. The company was founded in 2000 and is based in Goa, India.
The company makes money by selling its 'Truenat' platforms (devices) and disease-specific 'Truenat' test kits globally to public health programs, diagnostic laboratories, and private and public hospitals. It also generates revenue from other digital imaging solutions. Its main products and services include Truenat Platforms (Trueprep universal nucleic acid extraction device, Truelab analyzer - UnoDx, Duo, Quattro), Disease-specific Truenat Test Kits (for 30 diseases including TB, COVID, Hepatitis B and C, HIV, HPV), Radiology products (ultraportable X-ray systems, mobile digital X-ray systems, floor-mounted X-ray systems, ceiling-suspended X-ray systems, C-arm systems, DR retrofit panels) and Digital Health Platform ('ProDigi').
In its offer document the company lists its strengths as well-positioned in a large and growing molecular diagnostic market, in-house research and development (R&D) capabilities and developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform.
These open the registrar's and the exchanges' own websites. Molbio Diagnostics Limited is not affiliated with CAPITA1, and we never ask for your PAN or application number.
“Broker Consensus” is CAPITA1's algorithmic verdict from GMP, subscription, fundamentals & valuation — broker recommendations aren't in our data feed. GMP is an unofficial grey-market estimate. Not investment advice.
Curated by CAPITA1 · Updated 5 Sept 2026 by CAPITA1 desk (composed from filing)
For educational purposes only. Not investment advice.
Company financials (EPS, NAV, ratios) from Issuer DRHP figures, compiled from public IPO listings. Ratios computed at the upper price band; not investment advice.
Generate an AI read of the offer document — business, risks, promoters, use of funds and an educational verdict, with citations back into the filing.
Opening price on the first trading day. Not the current price, and not a return — what happened after listing is not shown here.
CAPITA1 desk — unofficial grey-market estimate — No exchange publishes a grey-market premium; this is not investment advice. Updated 11 Aug 2026, 08:47 am.
Subscription figures are not available for this issue.
New shares — the money goes to the company.
Existing shares — the money goes to the selling shareholders.
Per share, for the employee quota.
Regulatory maximum for one retail application.
As stated in the issue information filed with NSE.
Not Available
Market data: NSE (official calendar, issue filing and subscription) · CAPITA1 desk (GMP) · updated 18 Sept 2026, 01:43 pm
Fundamentals: Issuer DRHP figures, compiled from public IPO listings · fetched 14 Sept 2026, 03:57 pm
Corrected by CAPITA1: Sector · 05 Sept 2026, 12:54 pm
IPO calendar, issue details and subscription from NSE. Any grey-market premium shown is CAPITA1’s own unofficial estimate, collected daily from grey-market sources — not investment advice, and no exchange publishes one. Company fundamentals (financials, peers) are not part of the live feed.